Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDB-011 in Healthy Adults for Rift Valley Fever
NCT06925919Phase 1Active, not recruiting
- Sponsor
- IDBiologics
- Start
- Apr 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IDB-011 in Rift Valley fever (RVF) (6 arms), sponsored by IDBiologics. Primary endpoint: Evaluation of safety and tolerability at 1 year. Started Apr 2025; status: active, not recruiting.
02
Drugs
IDB-011
03
Conditions
Rift Valley fever (RVF)
Beyond the preview
Go deeper on NCT06925919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925919.